Intradermal injections that were one-fifth of the standard mpox vaccine dose generated antibody responses equivalent to those of subcutaneous injections of the standard dose at 6 weeks, based on from 225 US adults aged 18 to 50 years. No participants experienced serious adverse events related to the vaccine.

The was intended to clarify the safety and efficacy of dose-sparing strategies that could prolong the US supply of the Modified Vaccinia Ankara-Bavarian Nordic vaccine, marketed as Jynneos, amid the in 2022. The researchers presented their findings at the recent European Society of Clinical Microbiology and Infectious Diseases Global Congress.